Anti-Hypertensive Drugs - China

China

The Anti-Hypertensive Drugs market in China is expected to witness a significant increase in revenue, reaching a projected value of US$2.37bn in 2024.
This growth is anticipated to continue at a steady pace, with an annual growth rate (CAGR 2024-2028) of 0.52%.
As a result, the market volume is estimated to reach US$2.42bn by 2028.
In the global market, United States is expected to generate the highest revenue in the Anti-Hypertensive Drugs market, with a staggering US$12,290.00m in 2024.
China's booming pharmaceutical industry has seen a surge in the demand for anti-hypertensive drugs, driven by the country's aging population and increasing incidence of hypertension.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in China has been experiencing significant growth in recent years.

Customer preferences: As the population in China continues to age, the prevalence of hypertension has increased, leading to a higher demand for anti-hypertensive drugs. Additionally, with the growing middle class and increased access to healthcare, more people are seeking treatment for hypertension.

Trends in the market: In recent years, there has been a shift towards combination therapies, as they have been found to be more effective in controlling blood pressure. This has led to an increase in the use of fixed-dose combination drugs, which combine two or more drugs in a single pill. Additionally, there has been a trend towards the use of generic drugs, as they are more affordable than brand-name drugs.

Local special circumstances: One unique aspect of the Anti-Hypertensive Drugs market in China is the significant role played by traditional Chinese medicine. Many patients in China prefer to use traditional Chinese medicine to treat hypertension, and there has been a growing trend towards the integration of traditional Chinese medicine and Western medicine in the treatment of hypertension.

Underlying macroeconomic factors: The growth of the Anti-Hypertensive Drugs market in China can be attributed to several macroeconomic factors. The aging population and increasing middle class have already been mentioned, but another important factor is the government's push to improve healthcare access and affordability. In recent years, the Chinese government has implemented a number of policies aimed at improving healthcare, including expanding insurance coverage and increasing funding for healthcare facilities. These policies have helped to increase demand for anti-hypertensive drugs in China.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.